BioNTech (NASDAQ:BNTX) Given New $139.00 Price Target at Morgan Stanley

BioNTech (NASDAQ:BNTX) had its target price decreased by Morgan Stanley from $145.00 to $139.00 in a research note issued to investors on Tuesday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

Other equities research analysts have also issued research reports about the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $171.44 price objective on shares of BioNTech in a report on Tuesday. BMO Capital Markets lifted their price objective on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a report on Tuesday. Truist Financial initiated coverage on shares of BioNTech in a report on Friday, January 10th. They set a “buy” rating and a $172.00 price objective for the company. JPMorgan Chase & Co. decreased their price objective on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a report on Tuesday, November 26th. Finally, Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $143.65.

BioNTech Price Performance

BioNTech stock opened at $98.39 on Tuesday. The firm has a 50-day moving average price of $116.45 and a 200-day moving average price of $113.13. The firm has a market capitalization of $23.59 billion, a PE ratio of -46.85 and a beta of 0.30. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same quarter last year, the business posted $1.90 EPS. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. As a group, equities research analysts forecast that BioNTech will post -3.88 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Daiwa Securities Group Inc. grew its position in shares of BioNTech by 7.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company’s stock worth $221,000 after buying an additional 128 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock worth $419,000 after buying an additional 150 shares during the last quarter. Probity Advisors Inc. grew its position in shares of BioNTech by 8.5% in the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock worth $224,000 after buying an additional 154 shares during the last quarter. Midwest Professional Planners LTD. grew its position in shares of BioNTech by 5.8% in the 4th quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company’s stock worth $462,000 after buying an additional 222 shares during the last quarter. Finally, Perigon Wealth Management LLC grew its position in shares of BioNTech by 3.9% in the 4th quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company’s stock worth $666,000 after buying an additional 224 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.